Yet Another Pharma Firm Wants to Import Controlled Drugs
Published Date: 2/26/2025
Notice
Summary
S&B Pharma LLC, also known as Norac Pharma, wants to become an official importer of certain controlled drugs. People and companies involved with these drugs can share their thoughts or ask for a hearing by March 28, 2025. This move could affect drug supply chains and requires careful review but doesn’t mention any costs yet.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20552, Wellwise Pharmacy Inc.; Decision and Order
Wellwise Pharmacy in Texas had its DEA registration suspended and is facing revocation because it kept filling risky prescriptions for controlled drugs without checking warning signs. This affects the pharmacy’s ability to legally handle these medicines, protecting public health and safety. The decision took effect immediately in late 2025, stopping Wellwise from operating under its DEA license and signaling serious legal and financial trouble ahead.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
Previous / Next Documents
Previous: 2025-03061, Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC
Catalent Pharma Solutions, LLC wants to become an official importer of certain controlled substances, including the Schedule I drug Ibogaine. This affects companies and people involved in drug manufacturing who can comment or request a hearing by March 28, 2025. No fees or immediate changes happen now, but this is a key step in controlling drug imports.
Next: 2025-03065, Self-Regulatory Organizations; Cboe BZX Exchange, Inc.; Notice of Filing of a Proposed Rule Change, as Modified by Amendment No. 1, To List and Trade Options on the Grayscale Ethereum Trust ETF, the Grayscale Ethereum Mini Trust ETF, and the Bitwise Ethereum ETF
Cboe BZX Exchange is gearing up to let traders buy and sell options on three cool Ethereum ETFs: Grayscale Ethereum Trust, Grayscale Ethereum Mini Trust, and Bitwise Ethereum ETF. This means more ways for investors to play in the crypto world starting soon, with the SEC reviewing the plan now. If all goes well, expect these new options to hit the market shortly, opening fresh chances to invest and trade.